VCYT
Q3 2026 EPS Estimate
$0.44
Aug 5, 2026 · Reports after close
Revenue Estimate
$145M
FY2026E EPS$1.83
FY2027E EPS$1.89

Analyst Sentiment

Wall St. Consensus
Buy
20 analysts·High coverage
65
Score
13 Buy (65%)6 Hold (30%)1 Sell (5%)
Rating Breakdown
Strong Buy
00%
Buy
1365%
Hold
630%
Sell
15%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$37.00
-38.5%
Consensus
$52.00
-13.6%
Bull
$65.00
+8.0%
12-Month Target Range20 analysts
$37.00$52.00$65.00
Current $60.19Consensus
Current Price
$60.19
Above Consensus
$8.19

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+11.68%
EPS+3.68%
FY2028
Rev+9.80%
EPS+4.47%
FY2029
Rev+14.06%
EPS+4.95%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$587M$656M$720M$821M$903M
Low$583M$650M$718M$809M$890M
High$591M$661M$721M$835M$919M
EBITDA Avg$293M$328M$360M$410M$451M
Low$292M$325M$359M$404M$445M
High$295M$330M$361M$418M$459M
EBIT Avg$291M$325M$357M$407M$448M
Low$290M$323M$356M$401M$442M
High$293M$328M$358M$414M$456M
Net Income Avg$147M$153M$160M$167M$177M
Low$146M$149M$128M$164M$173M
High$148M$157M$192M$171M$181M
EPS Avg$1.83$1.89$1.98$2.08$2.19
Low$1.82$1.84$1.59$2.04$2.15
High$1.84$1.94$2.38$2.12$2.24
Analysts (Rev / EPS)8 / 68 / 67 / 53 / 16 / 1
Quarterly
MetricQ2 2026Q3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028
Revenue Avg$145M$149M$155M$152M$161M$166M$174M$163M
Low$144M$148M$153M$150M$160M$165M$172M$161M
High$145M$149M$156M$153M$163M$168M$175M$164M
EBITDA Avg$72M$74M$78M$76M$81M$83M$87M$81M
Low$72M$74M$77M$75M$80M$82M$86M$80M
High$72M$75M$78M$77M$81M$84M$88M$82M
EBIT Avg$72M$74M$77M$75M$80M$83M$86M$81M
Low$72M$74M$76M$75M$79M$82M$85M$80M
High$72M$74M$78M$76M$81M$83M$87M$81M
Net Income Avg$35M$35M$37M$36M$37M$38M$41M$42M
Low$34M$34M$36M$35M$37M$38M$40M$41M
High$35M$35M$37M$36M$38M$39M$41M$42M
EPS Avg$0.43$0.43$0.45$0.44$0.46$0.47$0.50$0.51
Low$0.42$0.42$0.45$0.43$0.45$0.47$0.49$0.51
High$0.43$0.44$0.46$0.44$0.46$0.48$0.51$0.52
Analysts (Rev / EPS)6 / 66 / 65 / 43 / 23 / 23 / 23 / 22 / 3

Earnings Surprises

Recent Analyst Actions

Jun 29, 2026Guggenheim
Veracyte price target raised to $65 from $45 at Guggenheim
Target:$65.00
+7.5%from $60.49
Jun 1, 2026Needham
Veracyte, Inc (VCYT) PT Raised to $57 at Needham
Target:$57.00
+17.8%from $48.38
May 6, 2026UBS
Veracyte price target raised to $52 from $48 at UBS
Target:$52.00
+31.8%from $39.44
May 6, 2026Canaccord Genuity
Veracyte price target raised to $42 from $40 at Canaccord
Target:$42.00
+27.4%from $32.97
Mar 5, 2026Morgan Stanley
Veracyte, Inc (VCYT) PT Lowered to $37 at Morgan Stanley
Target:$37.00
+6.7%from $34.68
Jan 5, 2026Guggenheim
Veracyte price target raised to $50 from $45 at Guggenheim
Target:$50.00
+16.4%from $42.95
Dec 1, 2025Morgan Stanley
Veracyte assumed with an Underweight at Morgan Stanley
Target:$48.00
+3.5%from $46.39
Nov 5, 2025UBS
Veracyte price target raised to $48 from $42 at UBS
Target:$48.00
+10.0%from $43.64
Nov 5, 2025Canaccord Genuity
Veracyte, Inc (VCYT) PT Raised to $43 at Canaccord Genuity
Target:$43.00
+19.0%from $36.12
Oct 20, 2025Canaccord Genuity
Veracyte initiated with a Hold at Canaccord
Target:$40.00
+11.6%from $35.83
Aug 8, 2025Morgan Stanley
Veracyte price target lowered to $28 from $29 at Morgan Stanley
Target:$28.00
+2.3%from $27.37
Nov 7, 2024Needham
Veracyte, Inc (VCYT) PT Raised to $44 at Needham
Target:$44.00
+22.7%from $35.85
Aug 12, 2024Morgan Stanley
Veracyte price target raised to $26 from $21 at Morgan Stanley
Target:$26.00
-11.6%from $29.41
May 4, 2022Morgan Stanley
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $23
Target:$23.00
+9.5%from $21.00
May 4, 2022Needham
Needham Maintains Buy on Veracyte, Lowers Price Target to $26
Target:$26.00
+21.2%from $21.46
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.